Core Insights - The Sci-Tech Innovation Board (STAR Market) has raised over 1.1 trillion yuan in total IPO and refinancing funds in its six years, with Jiangsu enterprises leading the way [1] - The number of Jiangsu companies listed on the STAR Market has grown from 5 to 114, making it the largest group in the country, with a total market capitalization exceeding 1 trillion yuan and cumulative fundraising surpassing 189.8 billion yuan [1][10] - Strategic emerging industries such as biomedicine, integrated circuits, and new energy are advancing simultaneously, showcasing the strong synergy between capital and industry in Jiangsu [1] Fundraising and Corporate Growth - The STAR Market's efficient and transparent mechanisms align well with the innovative characteristics of companies like Suzhou Huaxing Yuan Chuang Technology Co., Ltd., which became the first listed company on the STAR Market [2][3] - Huaxing Yuan Chuang raised 880 million yuan for investments in flat panel display and semiconductor testing production lines, establishing itself as an industry leader [2] - Other companies, such as Suzhou Nano Micro Technology Co., Ltd., have also leveraged STAR Market fundraising to enhance their R&D capabilities and expand their business [3] R&D Investment and Patent Accumulation - Jiangsu STAR Market companies have invested over 20 billion yuan in R&D and hold more than 20,000 patents, indicating strong technological capabilities [5] - Companies like Nanjing Mailland Medical Technology Co., Ltd. have seen significant growth, with R&D expenditures consistently representing a substantial portion of their revenue [5] - Suzhou Naxin Microelectronics Co., Ltd. has focused on the automotive sensor and signal chain industries, achieving a high R&D investment ratio and accumulating numerous patents [6][7] Government Support and Ecosystem Development - The development of STAR Market companies in Jiangsu is supported by government policies that provide financial assistance and resources for high-tech enterprises [8][9] - Various cities in Jiangsu have implemented distinct support measures, such as Suzhou's comprehensive nurturing system for potential listed companies and Nanjing's innovative financial service stations [9][10] - As of June 30, 2023, Jiangsu has 251 companies in the IPO counseling stage, accounting for 16% of the national total, with a significant portion of these being STAR Market candidates [10] Future Outlook - The STAR Market "Jiangsu Legion" is poised for further growth, aiming to convert laboratory patents into market value and enhance its overall innovation capabilities [11]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688273 证券简称：麦澜德 公告编号：2025-008 南京麦澜德医疗科技股份有限公司 ● 如在实施权益分派的股权登记日前公司总股本扣除公司回购专用证券账户中的股份数发生变动的，拟 维持每股分配比例不变，相应调整分配总额，并将另行公告具体调整情况。 ● 公司未触及《上海证券交易所科创板股票上市规则（2024年4月修订）》（以下简称《科创板股票上 市规则》）第12.9.1条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 经中兴华会计师事务所（特殊普通合伙）审计，南京麦澜德医疗科技股份有限公司（以下简称"公司"） 2024年度归属于上市公司股东的净利润为101,581,195.08元，截至2024年12月31日，母公司可供分配利 润为158,884,120.13元。经董事会决议，公司2024年度拟以实施权益分派股权登记日登记的总股本扣除 公司回购专用证券账户中的股份数为基数分配利润，本次利润分配的方案如下： 公司拟向全体股东每10股派发现金红利人民币4.00元（含税）。截至本公告披露日，公司总股本为 100,000,000 ...